Bilgic Alper, Sudhalkar Aditya, Sudhalkar Anand, Trivedi Megha, Vasavada Viraj, Vasavada Shail, Vasavada Vaishali, Srivastava Samaresh
Raghudeep Eye Hospital, Ahmedabad, India.
Sudhalkar Eye Hospital and Retina Centre, Baroda, India.
J Ophthalmol. 2020 Jan 31;2020:8359398. doi: 10.1155/2020/8359398. eCollection 2020.
To compare the outcomes of trabeculectomy using two different routes of bevacizumab administration as an adjunct in patients with primary open angle glaucoma.
Prospective, randomized, masked trial that included 180 eyes of 180 patients of documented primary open angle glaucoma were eligible for surgery. Patients were randomized to receive either a single intraoperative dose of subconjunctival bevacizumab (1.25 mg, Group I) or topical bevacizumab (5 mg/ml) for 30 days (Group II). One eye was randomly selected, if both were eligible for surgery. All patients underwent a complete ocular and systemic examination. Bleb morphology was examined and scored as per Moorfields system (MBGS) at 1, 3, 6, 12, 18, and 24 months postoperatively. Visual field, fundus photography, and disc analysis were performed. Outcome measures (at one year) included (1) comparison of bleb morphology in both groups, (2) proportion of patients achieving surgical success, and (3) side effects of treatment.
The groups did not differ with respect to age, sex, and crystalline lens status. Group II patients had significantly lower vascularity scores for central (=0.042) and peripheral bleb areas (=0.042) and peripheral bleb areas (=0.042) and peripheral bleb areas ( = 88) patients achieved average vascular scores of less than 2.5 (=0.042) and peripheral bleb areas ( = 88) patients achieved average vascular scores of less than 2.5 (. 94%; =0.042) and peripheral bleb areas (.
Topical bevacizumab gives a better vascularity profile at one year, but the studied routes appear equally safe and do not seem to affect the outcome in any other way.
比较在原发性开角型青光眼患者中，使用两种不同途径给予贝伐单抗作为小梁切除术辅助治疗的效果。
一项前瞻性、随机、双盲试验，纳入180例确诊为原发性开角型青光眼患者的180只眼，均符合手术条件。患者被随机分为两组，一组术中单次结膜下注射贝伐单抗（1.25毫克，第一组），另一组局部使用贝伐单抗（5毫克/毫升），持续30天（第二组）。若双眼均符合手术条件，则随机选择一只眼。所有患者均接受全面的眼部和全身检查。术后1、3、6、12、18和24个月，根据穆尔菲尔德系统（MBGS）检查并评估滤过泡形态并评分。进行视野、眼底照相和视盘分析。观察指标（一年时）包括：（1）比较两组滤过泡形态；（2）手术成功患者的比例；（3）治疗的副作用。
两组在年龄、性别和晶状体状态方面无差异。第二组患者中央滤过泡区域（=0.042）和周边滤过泡区域（=0.042）的血管化评分显著较低，周边滤过泡区域（=88）患者的平均血管化评分低于2.5（=0.042），周边滤过泡区域（=88）患者的平均血管化评分低于2.5（.94%；=0.042）和周边滤过泡区域（.
局部使用贝伐单抗在一年时的血管化情况更好，但所研究的给药途径似乎同样安全，且在其他方面似乎不影响治疗效果。
